Clinical implications of relationship between myeloperoxidase and acute coronary syndromes.
- Author:
Shi-hong LI
1
;
Yan-wei XING
;
Zhi-zhong LI
;
Shu-gong BAI
;
Jie WANG
Author Information
- Publication Type:Journal Article
- MeSH: Acute Coronary Syndrome; diagnostic imaging; enzymology; physiopathology; Adult; Angina, Unstable; diagnostic imaging; enzymology; Coronary Angiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; enzymology; Myocardial Ischemia; diagnostic imaging; enzymology; Peroxidase; blood; Troponin I; metabolism
- From: Chinese Journal of Cardiology 2007;35(3):241-244
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the clinical implications of relationship between myeloperoxidase and acute coronary syndromes (ACS).
METHODS176 consecutive patients who underwent coronary angiography for coronary atherosclerosis were divided into four groups according to the quartile of MPO Level. The characters and the relationship between MPO and the elements were studied in every group.
RESULTS(1) ACS rate (36.2%) in the fourth quartile group of MPO level was 6 times higher than that (5.2%) in the first quartile group of MPO level, P < 0.01. (2) Gensini score (65.6 +/- 30.3) in the fourth quartile group of MPO level was significantly higher than that (17.3 +/- 10.2) in the first quartile group (P < 0.01). WBC [(7.7 +/- 1.6) x 10(9)/L] in the fourth quartile group was also significantly higher than that [(6.6 +/- 1.8) x 10(9)/L] in the first quartile group, P < 0.05. (3) When TnI < or = 0.05 ng/ml, MPO level had a positive correlation with Gensini score (r = 0.321, P = 0.002) and WBC (r = 0.230, P = 0.025). (4) Kaplan-meier event rate curve showed that there was a significant difference of the terminus incident (death, no causing death AMI, vessel reestablish and incidence rate of CABG add up) between the groups > or = 62.9 AUU/L and < 62.9 AUU/L of MPO serum level at 6-month follow-up visit (chi(2) = 13.5, P = 0.01).
CONCLUSIONActivity level of MPO in human serum seems a good biomarker for diagnosing and predicting ACS, which may be especially helpful in predicting the risk of myocardial infarction in patients with acute chest pain during 6-month follow up.
